Alkermes plots $2.1B acquisition of Avadel and its long-acting narcolepsy drug Lumryz
22nd October 2025 Uncategorised 0With plans to pay $2.1 billion to acquire its Dublin, Ireland, neighbor Avadel Pharmaceuticals, Alkermes is hoping to gain an immediate growth driver in narcolepsy drug Lumryz. But perhaps more importantly, the deal lays the groundwork for the potential commercialization of Alkerme’s own narcolepsy candidate alixorexton.
More: Alkermes plots .1B acquisition of Avadel and its long-acting narcolepsy drug Lumryz
Source: fierce